Sarcoma Clinical Trials (2026): 409 Recruiting Interventional Studies
Last updated: March 9, 2026
Current Clinical Trial Landscape
Sarcoma subtypes:
- Soft tissue sarcoma — leiomyosarcoma, liposarcoma, synovial sarcoma, undifferentiated (407 trials)
- Osteosarcoma — bone cancer, most common in children/young adults (95 trials)
- Ewing sarcoma — bone/soft tissue, pediatric/young adult (45 trials)
Active research areas in 2026:
- Checkpoint inhibitors / immunotherapy (58 trials)
- Chemotherapy combinations (102 trials)
- Targeted therapies (MDM2, CDK4, tyrosine kinases)
- Neoadjuvant/perioperative approaches
Standard of care: Localized: surgery ± radiation. Metastatic soft tissue: doxorubicin-based chemotherapy. Osteosarcoma: MAP (methotrexate, doxorubicin, cisplatin).
Recruiting Trials by Treatment Setting
Localized / Neoadjuvant
Before or alongside surgery for localized disease:
- NCT06835049 - Total neoadjuvant treatment with hyperthermia in high-risk soft tissue sarcoma
- NCT06492954 - Atezolizumab + SBRT + surgery
First-Line Metastatic
For previously untreated advanced/metastatic sarcoma:
- NCT04605770 - Pemetrexed + cisplatin in soft tissue sarcoma
- NCT07359053 - Paclitaxel polymer micelles combination
Second-Line / Refractory
After progression on first-line therapy:
- NCT06389799 - Pemigatinib + retifanlimab in dedifferentiated liposarcoma
- NCT06171282 - Oncolytic virus (R130) for advanced bone/soft tissue sarcoma
- NCT07062003 - Minibeam radiation therapy for recurrent sarcoma
Trials by Sarcoma Subtype
Soft Tissue Sarcoma (407 trials)
Includes leiomyosarcoma, liposarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and others. View all →
Osteosarcoma (95 trials)
Primary bone cancer, most common in adolescents and young adults. View all →
Ewing Sarcoma (45 trials)
Bone and soft tissue sarcoma with characteristic EWSR1 translocation, primarily pediatric/young adult. View all →
Trials by Treatment Approach
Checkpoint Inhibitors (58 trials)
Immunotherapy shows variable activity across sarcoma subtypes; combinations are being explored. View all →
Chemotherapy (102 trials)
Doxorubicin, ifosfamide, gemcitabine, and other agents remain backbone of treatment. View all →
Targeted Therapy
MDM2 inhibitors (liposarcoma), CDK4/6 inhibitors, tyrosine kinase inhibitors, and other targeted agents.
- NCT06389799 - Pemigatinib (FGFR inhibitor) in dedifferentiated liposarcoma
Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.
Find Sarcoma Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific sarcoma subtype and treatment history.
Find Matching Trials
